BIO-Europe Spring® 2016: 4SC AG's CSO outlines epigenetics strategy

May 16, 2016

4SC AG Chief Science Officer Daniel Vitt speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden, outlining how the German cancer drug developer will use the EUR 29 million raised in September 2015 in an equity issue for pursuing epigenetic therapies, notably its lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma and its 4SC-202 asset in small-cell lung and hematological cancers, and its strategy for regulatory approval.

 


Want to elevate your brand and connect with potential partners? The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. Learn more here.

Previous Video
BIO-Europe Spring® 2016: AngioDesign tailoring next-generation ACE inhibitors
BIO-Europe Spring® 2016: AngioDesign tailoring next-generation ACE inhibitors

Mario Ehlers, the chairman and founder of Angio-Design (UK) speaks to Informa senior editor and writer Sten...

Next Video
BIO-Europe Spring® 2016: Agalimmune brings novel immune-oncology therapy from US to UK
BIO-Europe Spring® 2016: Agalimmune brings novel immune-oncology therapy from US to UK

Damian Marron, CEO of Agalimmune Ltd., speaks to Mike Ward, global director of content for Informa Pharma I...